134 related articles for article (PubMed ID: 17276985)
1. Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality.
Losasso C; Cretaio E; Palle K; Pattarello L; Bjornsti MA; Benedetti P
J Biol Chem; 2007 Mar; 282(13):9855-9864. PubMed ID: 17276985
[TBL] [Abstract][Full Text] [Related]
2. Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.
van der Merwe M; Bjornsti MA
J Biol Chem; 2008 Feb; 283(6):3305-3315. PubMed ID: 18056711
[TBL] [Abstract][Full Text] [Related]
3. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.
Fiorani P; Amatruda JF; Silvestri A; Butler RH; Bjornsti MA; Benedetti P
Mol Pharmacol; 1999 Dec; 56(6):1105-15. PubMed ID: 10570037
[TBL] [Abstract][Full Text] [Related]
4. Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin.
Woo MH; Vance JR; Marcos AR; Bailly C; Bjornsti MA
J Biol Chem; 2002 Feb; 277(6):3813-22. PubMed ID: 11733535
[TBL] [Abstract][Full Text] [Related]
5. Substitutions of Asn-726 in the active site of yeast DNA topoisomerase I define novel mechanisms of stabilizing the covalent enzyme-DNA intermediate.
Fertala J; Vance JR; Pourquier P; Pommier Y; Bjornsti MA
J Biol Chem; 2000 May; 275(20):15246-53. PubMed ID: 10809761
[TBL] [Abstract][Full Text] [Related]
6. Substitution of conserved residues within the active site alters the cleavage religation equilibrium of DNA topoisomerase I.
Colley WC; van der Merwe M; Vance JR; Burgin AB; Bjornsti MA
J Biol Chem; 2004 Dec; 279(52):54069-78. PubMed ID: 15489506
[TBL] [Abstract][Full Text] [Related]
7. Intragenic suppressors of mutant DNA topoisomerase I-induced lethality diminish enzyme binding of DNA.
Hann CL; Carlberg AL; Bjornsti MA
J Biol Chem; 1998 Nov; 273(47):31519-27. PubMed ID: 9813066
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of DNA topoisomerase I-induced cell killing in the yeast Saccharomyces cerevisiae.
Fiorani P; Bjornsti MA
Ann N Y Acad Sci; 2000; 922():65-75. PubMed ID: 11193926
[TBL] [Abstract][Full Text] [Related]
9. Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage.
Jacquiau HR; van Waardenburg RC; Reid RJ; Woo MH; Guo H; Johnson ES; Bjornsti MA
J Biol Chem; 2005 Jun; 280(25):23566-75. PubMed ID: 15817450
[TBL] [Abstract][Full Text] [Related]
10. Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I.
Fiorani P; Bruselles A; Falconi M; Chillemi G; Desideri A; Benedetti P
J Biol Chem; 2003 Oct; 278(44):43268-75. PubMed ID: 12904303
[TBL] [Abstract][Full Text] [Related]
11. DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.
Wright CM; van der Merwe M; DeBrot AH; Bjornsti MA
J Biol Chem; 2015 May; 290(19):12068-78. PubMed ID: 25795777
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico.
Tesauro C; Morozzo della Rocca B; Ottaviani A; Coletta A; Zuccaro L; Arnò B; D'Annessa I; Fiorani P; Desideri A
Mol Cancer; 2013 Sep; 12(1):100. PubMed ID: 24004603
[TBL] [Abstract][Full Text] [Related]
13. The human topoisomerase 1B Arg634Ala mutation results in camptothecin resistance and loss of inter-domain motion correlation.
D'Annessa I; Tesauro C; Wang Z; Arnò B; Zuccaro L; Fiorani P; Desideri A
Biochim Biophys Acta; 2013 Dec; 1834(12):2712-21. PubMed ID: 24096022
[TBL] [Abstract][Full Text] [Related]
14. Mutation of Gly717Phe in human topoisomerase 1B has an effect on enzymatic function, reactivity to the camptothecin anticancer drug and on the linker domain orientation.
Wang Z; D'Annessa I; Tesauro C; Croce S; Ottaviani A; Fiorani P; Desideri A
Biochim Biophys Acta; 2015 Aug; 1854(8):860-8. PubMed ID: 25910424
[TBL] [Abstract][Full Text] [Related]
15. The deubiquitinating enzyme Doa4p protects cells from DNA topoisomerase I poisons.
Fiorani P; Reid RJ; Schepis A; Jacquiau HR; Guo H; Thimmaiah P; Benedetti P; Bjornsti MA
J Biol Chem; 2004 May; 279(20):21271-81. PubMed ID: 14990574
[TBL] [Abstract][Full Text] [Related]
16. Directed evolution to increase camptothecin sensitivity of human DNA topoisomerase I.
Scaldaferro S; Tinelli S; Borgnetto ME; Azzini A; Capranico G
Chem Biol; 2001 Sep; 8(9):871-81. PubMed ID: 11564555
[TBL] [Abstract][Full Text] [Related]
17. Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality.
Woo MH; Losasso C; Guo H; Pattarello L; Benedetti P; Bjornsti MA
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13767-72. PubMed ID: 14585933
[TBL] [Abstract][Full Text] [Related]
18. Disulfide cross-links reveal conserved features of DNA topoisomerase I architecture and a role for the N terminus in clamp closure.
Palle K; Pattarello L; van der Merwe M; Losasso C; Benedetti P; Bjornsti MA
J Biol Chem; 2008 Oct; 283(41):27767-27775. PubMed ID: 18693244
[TBL] [Abstract][Full Text] [Related]
19. Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I.
Das BB; Sen N; Roy A; Dasgupta SB; Ganguly A; Mohanta BC; Dinda B; Majumder HK
Nucleic Acids Res; 2006; 34(4):1121-32. PubMed ID: 16488884
[TBL] [Abstract][Full Text] [Related]
20. A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay.
Stewart L; Ireton GC; Champoux JJ
J Biol Chem; 1999 Nov; 274(46):32950-60. PubMed ID: 10551862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
